[Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer].
To explore the predictive significance of FOXP3 Tregs in patients with breast cancer on neoadjuvant chemotherapy (NACT). A total of 78 newly diagnosed and untreated patients with invasive breast cancer were recruited for this retrospective study.FOXP3 Tregs were assessed by immunohistochemistry. The relationship between clinicopathological factors, FOXP3+ Tregs and pathological complete response (pCR) rate was analyzed. Among 78 patients with TAC neoadjuvant chemotherapy, the pCR rate was 19.2%. The pCR rate of patients with high expressions of FOXP3+ Tregs was significantly lower than that of those with low expressions of FOXP3+ Tregs (9.5% vs 30.5%, P = 0.023). FOXP3+ Tregs expression in breast cancer and efficacy of NACT were negatively correlated. FOXP3+ Tregs may serve as a predictor for assessing the efficacy of NACT.